Maternal BCG primes for enhanced health benefits in the newborn
The early-life mortality remains high in developing countries and nearly half of under-5 deaths occur in the neonatal period.1 Neonatal sepsis caused by a range of different bacterial agents, against which specific vaccines are not available, is a leading cause of death.2 A strategy to reduce early-life infection severity is the at-birth provision of live vaccines such as Oral Polio Vaccine (OPV) and Bacille Calmette-Gu érin (BCG).3 In a series of randomized controlled trials (RCTs) conducted by the Bandim Health Project (BHP, www.bandim.org) in Guinea-Bissau, BCG provided at hospital discharge a few days after birth reduced infectious disease mortality risk by 40% (95% Confidence Interval (CI): 11–60%)4, partic ularly due to protection against neonatal sepsis.
Source: Journal of Infection - Category: Infectious Diseases Authors: Frederik Schaltz-Buchholzer, Christian Bjerreg ård Øland, Mike Berendsen, Morten Bjerregaard-Andersen, Elise Brenno Stjernholm, Christian N Golding, Ivan Monteiro, Peter Aaby, Christine Stabell Benn Tags: Commentary Source Type: research
More News: Guinea Health | Guinea-Bissau Health | Hospitals | Infectious Diseases | Perinatology & Neonatology | Polio | Polio Vaccine | Vaccines